Introduction
Lung cancer is the leading cause of cancer death in patients over age forty, accounting for 226,160 new cancers and 160,340 deaths annually in the United States (1). Lung cancer is usually aggressive and characterized by early progression and metastases, as approximately 60% of patients with small cell lung cancer (SCLC) and up to 40% of patients with non-small cell lung cancer (NSCLC) will present with Stage IV disease at the time of diagnosis. The 5-year survival rate for lung cancer patients is only 15.9%, with most dying from metastasis (2). Early detection of lung cancer can improve outcome as evident from the National Lung Screening Trial (NLST, ACRIN A6654) that showed mortality can be reduced by 20% from screening high-risk patients with low dose helical computed tomography compared with chest x-ray (3) . Similarly, data from the International Early Lung Cancer Action Program (I-ELCAP) showed that Stage I lung cancer detected by annual low dose computed tomography scans improved survival with early treatment (4) . With the potential for early detection of lung cancer in high-risk populations, it is important to develop effective new therapeutic strategies.
Epidemiological studies indicate that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a significant decrease in cancer incidence and delayed progression in patients with colorectal, breast, lung, and other cancers (5, 6) .
The use of NSAIDs is also associated with reduced risk from cancer-related mortality and distant metastasis (7) (8) (9) . With regard to lung cancer, NSAIDs have been shown to reduce the incidence of lung carcinoma by 21%. The reduction in risk is increased to 32% when adjusted for smoking, and the efficacy is greatest in former smokers with a risk reduction of as much as 42% (10) . Rodent studies support these observations by demonstrating that NSAIDs inhibit tumor formation in carcinogeninduced models of lung tumorigenesis (11) (12) (13) . Unfortunately, the long-term use of NSAIDs and COX-2 inhibitors is not recommended because of potentially fatal gastrointestinal, renal, and cardiovascular toxicities associated with the depletion of physiologically important prostaglandins resulting from their COX-1 and -2 inhibitory activity (14, 15) .
Because smoking contributes to chronic pulmonary inflammation, it is logical that NSAIDs may inhibit lung cancer development through suppressing inflammatory mediators such as prostaglandins. However, some investigators have implicated alternative mechanisms by which NSAIDs may exert their antineoplastic activity, suggesting that it may be feasible to develop derivatives that do not inhibit COX-1 or COX-2 and have reduced toxicity (16) (17) (18) (19) . As support for a COX-independent mechanism, the sulfone metabolite of sulindac, which does not inhibit COX-1 and -2, has been reported to inhibit tumorigenesis in colon, mammary, lung and bladder models (20) (21) (22) . In a mouse model of tobacco carcinogen-induced lung tumorigenesis, sulindac sulfone strongly inhibited both tumor incidence and multiplicity (13) . Sulindac sulfone also inhibited tumor growth and metastasis that led to increased survival of rats with orthotopically implanted human lung tumors alone or in combination with docetaxel (23) (24) (25) . Although sulindac sulfone did not receive FDA approval for human use because of hepatotoxicity, these studies support the development of other non-COX-inhibitory derivatives of sulindac.
We recently described a N,N-dimethylethyl amine derivative of sulindac sulfide (SS) referred to as sulindac sulfide amide (SSA) that does not inhibit COX-1 or COX-2, yet inhibits colon tumor cell growth in vitro and in vivo (26) . Because of the strong efficacy of sulindac sulfone in lung cancer models, we conducted additional studies with SSA in human lung cancer cell lines to determine their level of sensitivity and to investigate the underlying mechanism of action. Here we describe a novel component of SSA-induced cytotoxicity which involves autophagy induction via suppression of Akt/mTOR signaling.
Materials and Methods

Drugs and Reagents
Sulindac sulfide amide (SSA) was synthesized and characterized as described previously (26) . Lipofectamine LTX and PLUS transfection reagents were purchased from Invitrogen. LC3 antibody was purchased from Novus Biologicals. Akt1/2/3 (panAkt) antibody was from Santa Cruz Biotechnology, MDM2 antibody was from EMD Biosciences and p62 antibody was from Abgent. All other antibodies were purchased from Cell Signaling Technology. pEGFP-LC3 and ptfLC3 plasmids were provided by Dr. John Shacka (University of Alabama at Birmingham, Birmingham, AL).
Constitutively-active Akt (Myr-Akt1, Addgene plasmid 9008) and empty vector (pcDNA3, Addgene plasmid 10792) plasmids were purchased from Addgene. Z-VAD-FMK was purchased from EMD Chemicals. All other drugs and reagents were purchased from Sigma-Aldrich unless otherwise stated. All compounds were dissolved in DMSO and the maximum final concentration of DMSO was 0.1% in all experiments.
Cell Culture
The human lung adenocarcinoma cell lines A549, H1299 and HOP-62 were obtained from the American Type Culture Collection and grown under standard cell culture conditions in RPMI 1640 containing 5% fetal bovine serum at 37°C in a humidified atmosphere with 5% CO 2 . All ATCC cell lines were expanded upon delivery, and numerous vials of low passage cells were preserved in liquid N2. No vial of cells was passaged for more than 2 months. Cell line characterization is performed by ATCC through STR profiling and re-authentication was not performed.
Cell Viability Assay
Tissue culture microtiter 96-well plates were seeded at a density of 5,000 cells per well and incubated for 18 to 24 h before being treated with the specified compound or vehicle control. The inhibition of cell growth caused by treatment was determined as described previously (27) . Caspase-Glo 3/7 Assay (Promega) as previously described (27) . PARP cleavage was measured by western blotting.
Apoptosis Assays
Cell Proliferation Assay
Cell proliferation was determined by using the Click-iT EdU Alexa Fluor 488 Proliferation Assay (Invitrogen). Cells were seeded at a density of 1x10 
Cell Cycle Measurements
Cells (2 × 10 5 to 3 × 10 5 ) were exposed to SSA, SS or vehicle control in 6-well plates and incubated for 24 h before analysis. The cells were trypsinized, washed with PBS, and fixed in 1 mL of 70% ethanol at 4°C overnight, followed by incubation with RNase (1 mg/ml) and staining with propidium iodide (40 μg/ml). DNA content was determined by flow cytometry using a Becton Dickinson FACSCalibur instrument.
Visualization of Intracellular Vacuoles
Acidic compartments were visualized by labeling the cells with Lyso-ID Green detection reagent (Enzo) according to the manufacturer's instructions. Nuclei were counterstained with DRAQ5. Images were obtained using an Evotec Opera confocal microscope with a 20x objective lens. For histological analysis, cells were harvested by CellStripper (CellGro), resuspended in PBS and smeared on microscope slides.
Cells were then immediately fixed in 10% neutral buffered formalin before being stained with hematoxylin and eosin.
Transmission Electron Microscopy
Cells were seeded at a density of 1x10 sequence for ATG7 and the non-silencing negative control siRNA were from Dharmacon Research.
Autophagic Imaging and Flux Assays
Cells seeded on coverslips at 50% confluency were transiently transfected with either the eGFP-LC3 or the tfLC3 plasmid. 24 hours after transfection, cell culture media was replaced with fresh and cells were treated with 5 μM SSA or vehicle control.
After 24 hours of treatment, cells were fixed in 10% neutral buffered formalin for 10 minutes, then rinsed with tris buffer and counterstained with DAPI. Slides were mounted using Fluoromount (Sigma). Imaging was performed on a Zeiss Axio Imager.M2 fluorescence microscope connected to a Zeiss AxioCam MRm camera. 
Western Blot Analysis
Immunoblotting was performed as described previously (27) . For p-mTOR, a 5% polyacrylamide gel was used in order to achieve proper separation.
Experimental Design and Data Analysis
Drug effects on cell growth and IC 50 values were determined as described previously (27) . All experiments were repeated a minimum of three times to determine the represent standard error of the mean (SE). Statistical analysis was performed using Student's t test with p < 0.05 deemed as statistically significant.
Results
In vitro tumor cell growth inhibitory activity of SSA
Previous molecular modeling studies revealed the importance of the carboxylic acid group on SS for inhibition of COX-1 and COX-2 (26). As depicted in Figure 1A values ranging from 44-52 μM. Next, we examined whether the growth inhibitory effects of SSA involved apoptosis induction and/or inhibition of proliferation. To assess the induction of apoptosis, cells were treated with SSA for 24 hours and the activation of effector caspases 3 and 7, which are specific biochemical markers of apoptotic cell death, was measured. As shown in Figure 1C , SSA treatment was not able to induce significant caspase activation at its IC 50 value in either cell type.
However, caspase activation by SSA was dose-dependent and higher concentrations were able to lead to significant levels of apoptosis compared to vehicle control. This activation, nonetheless, was low compared with that induced by SS and the apoptosis-inducing agent staurosporine. We also assessed PARP cleavage, which occurs downstream of caspase activation, as an additional specific marker of apoptosis by western blotting. We were able to detect cleaved PARP after 10 μM SSA treatment but not after 5 μM treatment ( Figure 1D) . A dose-dependent increase in PARP cleavage was also observed after SS treatment. As an additional marker of cell death, we measured Annexin-V and PI labeling after SSA treatment by flow cytometry. Interestingly, we observed a significant and dose-dependent increase in the extent of Annexin-V surface staining and PI labeling in all cell lines after 24 hours of SSA treatment at concentrations that suppressed growth and lower than those required for caspase activation ( Figure 1E ). SSA was also able to significantly and dose-dependently inhibit DNA synthesis in lung tumor cells as measured by EdU incorporation ( Figure 1F ). Furthermore, SSA treatment led to a dose-dependent increase in the percentage of cells in the G 0 /G 1 phase of the cell cycle at concentrations that suppressed growth ( Figure 1G ). Significant inhibition of DNA synthesis and G 0 /G 1 cell cycle arrest were also observed after single-dose SS treatment at 100 µM. These results indicate that the growth inhibitory activity of SSA is associated with inhibition of proliferation but not apoptosis after treatment at its IC 50 value, suggesting the involvement of alternative mechanisms of cell death.
SSA induces autophagy in lung adenocarcinoma cells
SSA-treated cells displayed a striking accumulation of vesicle-like structures within the cytoplasm that was readily apparent by phase contrast microscopy ( Figure 2A colocalization. While GFP-LC3 and mRFP-LC3-positive vesicles are apparent after SSA treatment (5 µM, 24 hours), many others that have lost GFP (arrows) and can be viewed as fusing with the lysosomes are observed ( Figure 3C ). These findings indicate that autophagosomes in SSA-treated cells are able to fuse with the lysosomes and that autophagic flux or turnover is increased.
Autophagy contributes to SSA-induced growth inhibition
The ability of SSA to induce autophagy in lung tumor cells lead us to next investigate the precise role of autophagy in its anticancer activity. Cancer cells, including lung cancer cells can undergo autophagy in response to various anticancer therapies.
This autophagic response can serve as a survival mechanism for the cell, or conversely, in some cases, as a non-apoptotic mechanism of programmed cell death (37) . To determine whether the autophagy seen in SSA-treated lung cancer cells is involved in cell death, we used siRNA to knock down Atg7, an essential protein for the induction of autophagy (38) . Atg7 siRNA was able to attenuate SSA-induced autophagy in A549 cells compared to scramble siRNA-transfected controls, as measured by western blotting ( Figure 4A ). Furthermore, knockdown of Atg7 resulted in a significant increase in cell viability after SSA treatment for 24 hours ( Figure 4B ).
To assess the role of apoptotic cell death in SSA-treated lung cancer cells, we used pan-caspase inhibitor Z-VAD-FMK (40 μM) to block caspase activity in A549 and inhibitory activity of SSA is predominantly mediated through autophagy and that cell death can occur independent of apoptosis.
SSA modulates autophagy and loss of viability in part by inhibiting
Akt/mTOR/p70S6k signaling
The Akt/mTOR pathway, a known regulator of autophagy and apoptosis, has been reported to be a target for sulindac sulfide (39, 40) , as well as the selective COX-2 inhibitor celecoxib (41, 42) . In addition, several chemotherapeutic agents have been shown to induce autophagy by inhibiting Akt and mTOR kinases (43) . Therefore, we evaluated the effects of SSA treatment on the phosphorylation of these kinases. As shown in Figure 5A Figure   5C ). These results suggest that the induction of autophagy and cell death by SSA is mediated through the Akt pathway. However, it needs to be noted that the blockage of autophagy and the rescue of viability are incomplete and additional mechanisms may be involved.
SSA is a more potent and effective inducer of autophagy than SS
We also evaluated SS for its ability to induce autophagy and inhibit Akt/mTOR signaling. Figure 6A shows that while SSA induced autophagy at concentrations equivalent to its IC 50 value for growth inhibition (5 µM), SS was unable to induce autophagy at its IC 50 In addition, SSA inhibited the phosphorylation of MDM2 oncoprotein at the Aktspecific Ser 166 residue, which increases its interaction with p300 allowing MDM2-mediated ubiquitination and degradation of p53 (47) . However, the effect of SS on MDM2 phosphorylation was minimal at the 100 µM concentration. Finally, levels of the anti-apoptotic and autophagy-inhibiting protein, survivin, were measured following SSA and SS treatment. We and others have reported that SS can suppress survivin levels leading to apoptosis and in some cases autophagic cell death (27, 48) . We found that SSA and SS potently suppress survivin levels in A549 lung tumor cells.
These results indicate that SSA is a potent inhibitor of Akt and mTOR effectors and suggest that these activities contribute to its antineoplastic activity. 
given NSAID to suppress tumor cell growth in vitro or in vivo far exceeds those required to inhibit COX-1 or COX-2 (49, 50). Moreover, NSAID analogs or metabolites that lack COX-inhibitory activity retain or have improved tumor cell growth inhibitory activity (17, 26, 51) . Our results with SSA suggest that it is feasible to chemically modify sulindac for developing safer and more efficacious drugs for lung cancer chemoprevention or therapy.
Despite lacking COX inhibitory activity, SSA was able to inhibit lung tumor cell growth much more potently than sulindac sulfide. The increase in potency was appreciable with a shift from IC 50 mechanism of action that impinges upon Akt/mTOR signaling. It is therefore plausible that the improved potency of SSA to inhibit Akt signaling may underlie its improved potency to induce autophagy and cell cycle arrest, and hence inhibit growth by dual mechanisms involving increased tumor cell death and the suppression of proliferation. In contrast, the predominant mechanism of cell death after SS treatment appears to be apoptosis.
The role of autophagy in tumor suppression is complex and likely involves several, sometimes paradoxical functions. Established tumors may utilize autophagy as an adaptive response against metabolic stress such as starvation, hypoxia, oxidative damage or chemotherapy (54) . In contrast, numerous researchers have demonstrated using in vitro and in vivo models that in response to certain chemotherapeutic agents, autophagy can also mediate cell death as a genuine effector mechanism (55, 56) . This has been dubbed autophagic cell death or programmed cell death type II. Alternatively, autophagy has been shown to act as an initial response mechanism for other agents, subsequently triggering apoptotic events (57) . As autophagy and apoptosis share some common effectors (e.g. Akt, Bcl-2, mTOR), it has been proposed that the nature and intensity of the initial stimulus may determine which form of cell death will arise. In certain contexts of apoptosis resistance, for example, autophagy has been shown to mediate cell death in response to agents that would otherwise lead to apoptosis in naïve cells (58) . This suggests that autophagy can function as a distinct cell death modality, which can be exploited for novel anticancer drug strategies to circumvent resistance. The ability of SSA to induce autophagy has important implications for its development as a therapeutic agent for lung cancer, alone or in combination with standard chemotherapy. Our findings demonstrate that SSA can eliminate NSCLC cells through the induction of autophagy. We propose that this is a desirable property especially in the case of lung cancer chemotherapy because drugs commonly used in the clinic such as paclitaxel, gemcitabine and EGFR inhibitors often lead to the development of apoptosis-resistant tumors (59) . Recent studies have shown that apoptosis resistance can develop as a result of Akt or Bcl-2 upregulation, and that these tumors can be chemosensitized by inducers of autophagy (60) (61) (62) .
In summary, our findings support the potential of SSA as a novel agent for the prevention and/or treatment of lung cancer. We provide proof-of-concept evidence 
